Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982583 | 0.86 | TAAR1 (0.42) | NPC1SMN1; SMN2ALDH1A1TSHRHTT | |
| SCHEMBL13992225 | 0.86 | MEN1 (0.44) | MEN1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL13992214 | 0.86 | MEN1 (0.47) | MEN1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL21803201 | 0.85 | RAB9A (0.49) | MEN1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL13316992 | 0.83 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1TSHRHTTATM | |
| SCHEMBL13298070 | 0.82 | THRB (0.46) | MEN1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL1682780 | 0.78 | L3MBTL1 (0.44) | MEN1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL1161703 | 0.78 | TAAR1 (0.46) | MEN1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL241884 | 0.77 | CA1 (0.52) | LMNAKMT2ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL13992219 | 0.76 | CA12 (0.39) | ALDH1A1CYP3A4CYP2D6CYP2C9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110862372-B | Synthesis of clopidogrel intermediate (S) -2- (2-thiophenoethylamine) - (2-chlorophenyl) -methyl acetate | 江西川奇药业有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-110862372-A | Synthesis of clopidogrel intermediate (S) -2- (2-thiophene ethylamino) - (2-chlorphenyl) -methyl acetate | 江西川奇药业有限公司 | 2020-03-06 | — | — | CN | claimed |
| EP-2585428-B1 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-05-10 | — | — | EP | claimed |
| CN-103509037-B | A kind of clopidogrel and the preparation method of intermediate thereof | 山东鲁药制药有限公司 | 2016-08-31 | — | — | CN | claimed |
| CN-103119015-B | Method for resolving nitrogen substituted (S) -5-alkoxy-2-aminotetralin derivatives | UCB PHARMA GMBH (DE) | 2016-01-27 | — | — | CN | claimed |
| CN-103044444-B | Synthesis method of high-purity I-type (+)-(S)-clopidogrel hydrogen sulfate | SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD | 2015-04-15 | — | — | CN | claimed |
| US-8981121-B2 | Process for the preparation of nitrogen substituted aminotetralins derivatives | UCB PHARMA GMBH (DE) | 2015-03-17 | — | — | US | claimed |
| CN-103509037-A | Preparation method of clopidogrel and intermediate thereof | SHANDONG LUYAO PHARMACEUTICAL CO LTD | 2014-01-15 | — | — | CN | claimed |
| EP-2585428-A2 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB Pharma GmbH (DE) | 2013-05-01 | — | — | EP | claimed |
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | UCB PHARMA GMBH (DE) | 2013-04-25 | — | — | US | claimed |
| CN-101560202-B | Preparation method of 2- (2-thienyl) ethanol p-toluenesulfonate | Suzhou lixin pharmaceutical co ltd | 2012-05-09 | — | — | CN | claimed |
| WO-2011161255-A2 | NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES | UCB PHARMA GMBH (DE) | 2011-12-29 | — | — | WO | claimed |
| US-20110313176-A1 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | claimed |
| WO-2010073124-A2 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-07-01 | — | — | WO | claimed |
| CN-101560202-A | Preparation method of 2-(2-thienyl) ethyl-4-methylbenzenesulfonate | SUZHOU LIXIN PHARMACEUTICAL CO (CN) | 2009-10-21 | — | — | CN | claimed |
| WO-2009056791-A1 | PROCESSES FOR PREPARING PHARMACEUTICAL COMPOUNDS | PLIVA HRVATSKA D.O.O. (HR) | 2009-05-07 | — | — | WO | claimed |
| EP-1232152-B1 | IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS | ADERIS PHARMACEUTICALS INC (US) | 2004-02-04 | — | — | EP | claimed |
| EP-1232152-A1 | IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS | Aderis Pharmaceuticals, Inc. (US) | 2002-08-21 | — | — | EP | claimed |
| US-6372920-B1 | ALKYLATING 2-AMINOTETRALIN IN PRESENCE OF BASE SELECTED FROM ALKALI METAL CARBONATES AND BICARBONATES, WHEREIN AMOUNT OF BASE IS LESS THAN ABOUT 1.9-FOLD MOLAR EXCESS WITH RESPECT TO AMOUNT OF 2-AMINOTETRALIN | ADERIS PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | claimed |
| WO-2001038321-A1 | IMPROVED PROCESS FOR PREPARING NITROGEN-SUBSTITUTED AMINOTETRALINS | ADERIS PHARMACEUTICALS, INC. (US) | 2001-05-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | AANAT, AADAT, ASNS | MEN1 1547/4885LMNA 2631/4885KMT2A 2007/4885 |
| US-20110313176-A1 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC4R, AVPR2, MC5R | MEN1 536/4885LMNA 4108/4885KMT2A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.